2018 Publications

Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Kangiser, M. M.; Dwoskin, L. P.; Zheng, G.; Crooks, P. A.; Stairs, D. J.*
Behav. Pharmacol. 2018, 29, 87-97. Doi: 10.1097/FBP.0000000000000340

Novel scaffold for lead compounds to treat methamphetamine use disorders.

Lee, N-R.; Zheng, G.; Crooks, P. A.; Bardo, M. T.; Dwoskin, L. P.*
AAPS J. 2018, 20, 29. Doi: 10.1208/s12248-018-0192-y

New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma cells and embryonic carcinoma cells.

Hoang, N.; Zhang, X.; Zhang C.; Vo, V.; Leng, F.; Saxena, L.; Yin, F.; Lu, F.; Zheng, G.; Bhowmik, P.; Zhang, H.*
Bioorg. Med. Chem. 2018, 26, 1523-1537. Doi: 10.1016/j.bmc.2018.01.031

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.

Maggio, S. E.; Saunders, M. A.; Baxter, T. A.; Nixon, K.; Prendergast, M. A.; Zheng, G.; Crooks, P.; Dwoskin, L. P.; Slack, R. D.; Newman, A. H.; Bell, R. L.; Bardo, M. T.*
Psychopharmacology. 2018, 235, 1439-1453. Doi: 10.1007/s00213-018-4853-4

Oxidation resistance 1 is a novel senolytic target.

Zhang, X(in).; Zhang, S.; Liu X.; Wang, Y.; Chang, J.; Zhang, X(uan).; Mackintosh, S. G.; Tackett, A. J.; He, Y.; Lv, D.; Laberge, R.; Campisi, J.; Wang, J.; Zheng, G.; Zhou, D.*
Aging Cell. 2018, 17, e12780. Doi: 10.1111/acel.12780

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.

Liu X.; Wang, Y.; Zhang, X(uan).; Gao, Z.; Zhang, S.; Shi, P.; Zhang, X(in).; Song, L.; Hendrickson, H.; Zhou, D.; Zheng, G.*
Bioorg. Med. Chem. 2018, 26, 3925-3938. Doi: 10.1016/j.bmc.2018.06.013

An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.

Maggio, S. E.; Saunders, M. A.; Nixon, K.; Prendergast, M. A.; Zheng, G.; Crooks, P.; Dwoskin, L. P.; Bell, R. L.; Bardo, M. T.*
Drug Alcohol Depend. 2018, 193, 154-161. Doi: 10.1016/j.drugalcdep.2018.09.008

Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 – M5 muscarinic acetylcholine receptors.

Lee, N-R.; Gujarathi, S.; Bommagani, S.; Siripurapu, K.; Zheng, G.; Dwoskin, L. P.*
Bioorg. Med. Chem. Lett. 2018, 29, 471-476. Doi: 10.1016/j.bmcl.2018.12.022